Press release
Deadline on June 4th coming up in Lawsuit for Investors in shares of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT)
A Deadline is coming up on June 4, 2024 in the lawsuit for certain investors in Checkpoint Therapeutics, Inc. (NASDAQ: CKPT).
Investors who purchased shares of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) have certain options and there are strict and short deadlines running. Deadline: June 4, 2024. NASDAQ: CKPT stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Southern District of New York the plaintiff alleges on behalf of purchasers of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) common shares between March 10, 2021 and December 15, 2023, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between March 10, 2021 and December 15, 2023, the defendants made false and/or misleading statements and/or failed to disclose that Checkpoint had overstated its oversight of, and/or its establishment of adequate manufacturing standards and controls over, its third-party contract manufacturers, that accordingly, there were one or more issues with the Company's third-party contract manufacturing organization ("CMO") for cosibelimab, that all the foregoing reduced the likelihood that the FDA would approve the cosibelimab BLA in its present form, that as a result, the manufacturing, regulatory, and commercial prospects of cosibelimab were overstated, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Deadline on June 4th coming up in Lawsuit for Investors in shares of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) here
News-ID: 3509104 • Views: …
More Releases from Shareholders Foundation, Inc.
Investigation Alert: Long-Term Investors in shares of First Solar, Inc. (NASDAQ: …
An investigation was announced for current long-term investors in shares of First Solar, Inc. (NASDAQ: FSLR) concerning potential breaches of fiduciary duties by certain directors and officers of First Solar, Inc.
Investors who are current long term investors in First Solar, Inc. (NASDAQ: FSLR) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
Phoenix, AZ based First Solar, Inc., a solar technology…
Lawsuit Alert: Investors who lost money with Baidu, Inc. (NASDAQ: BIDU) should c …
An investor, who purchased shares of Baidu, Inc. (NASDAQ: BIDU), filed a lawsuit over alleged violations of Federal Securities Laws by Baidu, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Baidu, Inc. (NASDAQ: BIDU) have certain options and for certain investors are short and strict deadlines running. Deadline: November 13, 2026. NASDAQ: BIDU investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Lawsuit filed for Investors who lost money with shares of Doximity, Inc. (NYSE: …
An investor, who purchased shares of Doximity, Inc. (NYSE: DOCS), filed a lawsuit over alleged violations of Federal Securities Laws by Doximity, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Doximity, Inc. (NYSE: DOCS) have certain options and for certain investors are short and strict deadlines running. Deadline: November 16, 2026. NYSE: DOCS investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Blaize Holdings, Inc. (NASDAQ: BZAI) Investor Alert: Deadline in Lawsuit on Octo …
A deadline is coming up on October 5, 2026 in the lawsuit filed for certain investors of Blaize Holdings, Inc. (NASDAQ: BZAI) over alleged securities laws violations by Blaize Holdings, Inc.
Investors who purchased shares of Blaize Holdings, Inc. (NASDAQ: BZAI) have certain options and there are strict and short deadlines running. Deadline: October 5, 2026. Blaize Holdings, Inc. (NASDAQ: BZAI) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or…
More Releases for Checkpoint
Checkpoint Inhibitors Pipeline & Competitive Landscape Report 2026 | DelveInsigh …
DelveInsight's, "Checkpoint Inhibitors Competitive landscape 2026" report provides comprehensive insights about 50+ companies and 60+ drugs in Checkpoint Inhibitors Competitive landscape. It covers the Checkpoint Inhibitors Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the full insights into the evolving Checkpoint Inhibitors Pipeline and discover which companies are leading the innovation race @ Checkpoint Inhibitors Competitive…
Checkpoint Inhibitors Pipeline & Competitive Landscape Report 2025
DelveInsight's, "Checkpoint Inhibitors Competitive landscape 2025" report provides comprehensive insights about 50+ companies and 60+ drugs in Checkpoint Inhibitors Competitive landscape. It covers the Checkpoint Inhibitors Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the full insights into the evolving Checkpoint Inhibitors Pipeline and discover which companies are leading the innovation race @ Checkpoint Inhibitors Competitive…
Checkpoint Inhibitors Market Report 2024: Advancing Cancer Treatments
The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Checkpoint Inhibitors Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $55.64 billion In 2028 At…
Checkpoint Inhibitors Competitive Landscape Report 2023
DelveInsight's, "Checkpoint Inhibitors Competitive Landscape 2023" report provides comprehensive insights about 180+ Checkpoint Inhibitors Companies and 250+ drugs in the Checkpoint inhibitors Competitive landscape. It covers the Checkpoint Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Checkpoint Inhibitors Competitive Landscape Report
• DelveInsight's Checkpoint Inhibitors report depicts a robust space with 180+ Glioma…
Checkpoint Inhibitor Refractory Cancer Market
Checkpoint Inhibitor Refractory Cancer Market Overview
The global Checkpoint Inhibitor Refractory Cancer Market is poised for significant growth, anticipating a high CAGR during the forecast period from 2023 to 2030.
Understanding Checkpoint Inhibitor Refractory Cancer
Refractory cancer, which might not respond to treatments immediately or might develop resistance later, has driven significant growth and transformation in the global checkpoint inhibitor refractory cancer market. The interest of oncologists in the potential antitumor activity of…
Immune Checkpoint Inhibitors Market: Current Evidence And Future Perspectives Of …
Stratagem Market Insights delivers key insights for the Immune Checkpoint Inhibitors market in its published report, which include global industry analysis, Size, Growth, Opportunities, Emerging Trends, Challenges, and Geographic Regions over the forecast period (2021-2028). In terms of revenue, the global Immune Checkpoint Inhibitors market is projected to grow at a CAGR of XX% during the forecast period, owing to several factors about which SMI offers detailed insights and forecasts…
